PROTON PUMP INHIBITORS MARKET ANALYSIS
Global proton pump inhibitors market is estimated to be valued at USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Discover market dynamics shaping the industry: Request sample copy
Proton pump inhibitors are widely used for treatment of acid reflux diseases, peptic ulcers and other gastric disorders. Increasing geriatric population who are more prone to such diseases, increasing awareness about treatment options and growing healthcare expenditure in emerging nations can boost demand for proton pump inhibitors. However, availability of alternative therapies and patent expiration of major drugs can hamper the market growth. Strong pipeline of novel drug candidates and increasing focus on emerging markets by key market players can offer new opportunities in the near future.
Rising prevalence of gastrointestinal disorders
Rising prevalence of gastrointestinal disorders such as acid reflux, heartburn and ulcers can drive the market growth. In 2022, according to the global guidelines published by World Gastroenterology Organization, over 25% of the world's population suffer from gastrointestinal issues at some point of life and this boosts demand for proton pump inhibitors that offer heartburn relief. Proton pump inhibitors work by reducing the amount of acid produced in the stomach and provide symptomatic relief for acid-related disorders. Various factors such as changing dietary habits, increased stress levels, consumption of alcohol, tobacco use and lack of physical activity contributes to increase in gastrointestinal disorders. According to the data published by World Health Organization, developing economies like India and China that are shifting towards more sedentary lifestyles and urbanization witness rise in obesity, and this boosts cases of acid reflux disease. For instance, in August 2023, according to the article published by Jaypee Hospital, there has been increase in the incidence of gastrointestinal (GI) disorders, prompting significant health concerns. The functionality of the GI system, which encompasses digestion, absorption, and waste elimination, is crucial for overall health. The increase in GI issues is attributed to various factors such as dietary habits, lifestyle shifts, environmental factors, and genetic predispositions.
Get actionable strategies to beat competition: Request sample copy
Launch of new products
Global proton pump inhibitors market is witnessing growth due to rising number of new product launches by major pharma companies. PPIs are commonly used to reduce excess stomach acid and provide relief from conditions like acid reflux, ulcers and gastroesophageal reflux disease (GERD). Many companies are focusing on developing advanced and more effective PPI formulations to expand their portfolios and market share. Some new products offer dual relief from acid reflux and heartburn symptoms with just one pill. These work faster and for longer duration as compared to existing drugs. Other new launches combine PPIs with other medicines to manage concurrent conditions like H. pylori infection, which causes ulcers. Some companies are also developing PPIs with improved tolerability and reduced interaction with other medications. For instance, in March 2021, Xiromed LLC, a generic division of Insud Pharmaceuticals, introduced Omeprazole Delayed-Release Capsules, 20mg, as a generic equivalent of Prilosec.
Key Takeaways from Analyst:
Rising geriatric population who are more susceptible to acid reflux and ulcers can boost demand for proton pump inhibitors. Growing adoption of sedentary lifestyles and consumption of spicy and oily foods, which can trigger acid reflux, can also drive the market growth. Furthermore, increasing awareness about treatments of acid reflux diseases and their OTC availability makes PPIs more accessible.
The adverse effects of long-term PPI usage can hamper the market growth. Long-term use has been linked to increased risk of fractures, pneumonia, hypomagnesemia and vitamin B12 deficiency. The availability of cheaper generic alternatives provide competition to branded drugs.
Asia Pacific region excluding Japan is expected to emerge as the fastest growing market, owing to large patient pools, rising healthcare expenditure and expanding medical insurance coverage in many countries. North America currently dominates the market followed by Europe.
Market Challenges: Patent expiration of major drugs
The expiration of patents on major drugs can hamper the global proton pump inhibitors market growth. When blockbuster drugs lose their patent exclusivity, generic manufacturers are able to produce affordable copies of the original drug. This increases competition and puts downward pressure on prices. For example, the patents on Nexium (esomeprazole) expired in Europe and Japan in 2014 and in the U.S. in 2015. Nexium had been one of the top selling drugs globally, with annual sales of over US$ 6 billion. The entry of generic versions of esomeprazole led to an immediate decline in sales for the branded Nexium product. Other major PPIs that have faced generic competition include Prilosec (omeprazole), Prevacid (lansoprazole) and Aciphex (rabeprazole).
Market Opportunities: New research on dual therapy drugs
New research is exploring the potential of dual therapy drugs that can target both gastric acid secretion and gastric epithelial protection. This offers a major opportunity for proton pump inhibitors market globally. Dual therapy drugs have shown promising results in clinical trials at effectively reducing gastroesophageal reflux disease symptoms as compared to conventional PPIs alone. By addressing both acid suppression and mucosal defense, dual therapies may provide better symptom relief for patients with acid-related disorders. This novel drug category can help meet some of the current limitations of long-term PPI use, such as reduced effectiveness over time, lack of mucosal healing, and implications for antibiotic resistance with prolonged acid suppression. If approved, dual therapies could capture a sizable portion of the market within 5-10 years. In 2021, according to a report published by United Nations, over 300 million people experience gastroesophageal reflux disease globally each year. The condition severely impacts quality of life and daily activities for many sufferers. Dual therapies may offer improved outcomes for this large patient group where conventional PPIs are unable to fully control acid reflux symptoms. Their increased clinical efficacy could increase patient adherence to treatment regimens. This impacts overall disease management costs imparted by frequent physician visits and delayed symptom resolution with current standard of care options.
Discover high revenue pocket segments and roadmap to it: Request sample copy
Insights, By Type - Brand loyalty boosts omeprazole segment growth
In terms of type, omeprazole segment is estimated to contribute the highest market share of 30.2% in 2024, owing to its strong brand recognition and loyalty among consumers. As the first PPI drug to be introduced, omeprazole established itself as the gold standard for ulcer and GERD treatment. Despite the introduction of newer PPIs, omeprazole continues benefiting from the brand equity and trust it had built among consumers. Patients who were initially prescribed omeprazole have remained faithful to the brand even after their conditions were resolved, preferring its proven efficacy and tolerability over alternatives. Besides patients, even physicians have high familiarity with omeprazole's clinical profile, and are more likely to prescribe it as the first line treatment. Omeprazole also benefits significantly from brand pull effect via word-of-mouth recommendations to new patients within social and professional circles. Being an older molecule, omeprazole faces relatively less competition from generics as compared to other PPIs.
Insights, By Disease Indication - Acid reflux indications boosts ulcers segment growth
In terms of disease indication, ulcers segment is estimated to contribute the highest market share of 40.21% in 2024, owing to rising prevalence of gastroesophageal reflux disease (GERD). GERD is a chronic condition where stomach acid backs up into the throat. Left untreated, it can cause damage to the esophagus over time, often leading to ulcers. With lifestyle changes like increased stress levels, late-night eating, excess alcohol/tobacco consumption, and physical inactivity becoming common globally, cases of GERD have doubled over the last two decades. As GERD is a primary risk factor for ulcers, its rising incidence has directly boosted the number of ulcers diagnoses and treatments. PPI drugs like omeprazole that provide effective relief from gastrointestinal acidity are first-line choices for managing both GERD and resulting ulcers. Provdied their ability to heal existing ulcers and also prevent relapse, PPIs now constitute over 80% of total ulcer treatment regimens.
Insights, By Dosage Form - User-friendliness boosts tablet segment growth
In terms of dosage form, tablets segment is estimated to contribute the highest market share of 60.21 % in 2024 ,owing to their convenience and popularity over other formats. Being oral solid dosage, tablets offer ease of ingestion and consistent dosing without any complex administration procedures. This provides improved treatment adherence for PPIs which need to be taken regularly over long periods. Additionally, tablets have a strong ubiquitous presence across global healthcare systems relative to other formats. Their universal acceptance is aided by capabilities for mass production, long shelf life, and cost-effective distribution even in remote areas. Capsules are equally portable but are a less preferred format due to difficulties faced by some patients in swallowing them. Injections have limited scope as PPI therapy typically involves chronic outpatient use. As tablets meet treatment needs in the most hassle-free manner, these emerge as the dominant segment.
To learn more about this report, Request sample copy
North America has established itself as the dominant regional market for proton pump inhibitors globally with an estimated market share of 38.3 % in 2024. The regional market growth can be attributed to favourable reimbursement policies and higher healthcare spending in the U.S. and Canada. Major pharmaceutical companies have their origins and headquarters in the region, facilitating high R&D investments and strong product pipelines. There is a significant presence of industry leaders like Pfizer and AstraZeneca that enjoy brand loyalty for their established products. Moreover, the region promotes medical awareness and adoption of preventive healthcare measures for gastric issues like ulcers. This has enabled proton pump inhibitors to become a mainstream therapy choice. However, pricing pressures from generics and competitive brands may challenge future growth prospects for innovator products in North America.
Asia Pacific region has emerged as the fastest growing market for proton pump inhibitors worldwide. Rapidly increasing healthcare expenditures, rising obesity due to changing lifestyles and diet habits have boosted demand for acid-reducing drugs. Countries like India, China and Japan have a large patient pool suffering from gastric ailments, owing to their aging populations and hereditary risks. Local companies in these markets have strengthened their presence through cost-effective generic versions. International brands are also targeting this region through product licensing, joint ventures and imports. However, lack of stringent regulations and enforcement has promoted proliferation of poor quality copies. This poses a significant threat to established innovators while benefiting local unorganized players.
Proton Pump Inhibitors Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 3.81 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.4% | 2031 Value Projection: | US$ 5.50 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AstraZeneca, Pfizer, Takeda Pharmaceutical Company Limited, Novartis AG, Procter & Gamble, Johnson & Johnson, GlaxoSmithKline plc, Bayer AG, Eisai Co., Ltd., Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Sanofi, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Allergan, Inc., Cadila Pharmaceuticals, Daiichi Sankyo Company, Limited, Perrigo Company PLC |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Global Proton Pump Inhibitors Market involves the manufacturing and sale of proton pump inhibitor drugs that reduce gastric acid production. These drugs help treat acid reflux disease, ulcers, and other gastrointestinal issues by inhibiting the hydrogen-potassium adenosine triphosphatase enzyme system of gastric parietal cells. Major players in this market offer prescription and over-the-counter medications that provide significant relief from symptoms of acid-related disorders for millions of patients worldwide.
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 